

AWARD NUMBER: W81XWH-17-1-0477

TITLE: Validating Community-Based Measures of Activity in Ambulatory Duchenne Muscular Dystrophy

PRINCIPAL INVESTIGATOR: McDonald, Craig M.

CONTRACTING ORGANIZATION: University of California Davis, Sacramento, CA

REPORT DATE: August 2021

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE August 2021		2. REPORT TYPE Annual Report		3. DATES COVERED 01Sep2020-31Aug2021	
4. TITLE AND SUBTITLE Validating Community-Based Measures of Activity in Ambulatory Duchenne Muscular Dystrophy				5a. CONTRACT NUMBER W81XWH-17-1-0477	
				5b. GRANT NUMBER MD160094	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Craig McDonald, MD Erik Henricson, PhD, MPH E-Mail: ehenricson@ucdavis.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) UC Davis Dept. of Physical Medicine & Rehabilitation 4860 Y Street, Suite 3850 Sacramento, CA 95817				8. PERFORMING ORGANIZATION REPORT NUMBER MD160094Y2	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT This research project will validate use of patient generated step and activity data for data collection at the point-of-care to support use of stride rate patterns as an outcome measure for ambulatory patients with DMD. We will include step activity monitoring by laboratory and consumer level step monitoring devices that can feed data through Apple HealthKit into the UC Davis instance of the Epic electronic medical record system. Up to 60 ambulatory patients with DMD will be recruited to represent the early, middle and late stages of the progressive loss of ambulation in DMD. Up to 150 control patients will be recruited and split into similar age ranges. Participants will be assessed using step monitoring devices and traditionally performed clinical outcome measures, followed by community monitoring. StepWatch™ data collected from two previously enrolled cohorts of children with DMD will also be used for longitudinal analyses and determination of responsiveness to steroid treatment.					
15. SUBJECT TERMS None listed.					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT Unclassified	18. NUMBER OF PAGES 12	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT Unclassified	b. ABSTRACT Unclassified	c. THIS PAGE Unclassified			19b. TELEPHONE NUMBER (include area code)

TABLE OF CONTENTS

	<u>Page</u>
1. Introduction	4
2. Keywords	4
3. Accomplishments	5
4. Impact	8
5. Changes/Problems	9
6. Products	9
7. Participants & Other Collaborating Organizations	10
8. Special Reporting Requirements	10
9. Appendices	10

1. INTRODUCTION:

Background: Development of novel technologies and therapeutic agents to treat Duchenne muscular dystrophy (DMD) have increased interest by regulatory bodies such as the Food and Drug Administration in the development of “clinically-meaningful” study endpoints for clinical trials. There is a need for the development of valid measures of ambulatory ability in very young children while effectively evaluating treatment effects in clinical trials.

Objective: This proposal focuses on validating the use of patient generated step and activity data to facilitate future data collection at the point-of-care to support the development of stride rate patterns as an outcome measure for ambulatory patients with DMD. It is to include step activity monitoring by StepWatch™ and a consumer level step monitoring devices (Garmin VivoActiveHR and Polar M400 activity watches and the Polar StrideSensor activity monitor) that can feed data through Apple HealthKit into the UC Davis instance of the Epic electronic medical record system. Up to 60 ambulatory patients with DMD will be recruited to represent the early, middle and late stages of the progressive loss of ambulation in DMD. Patients will be sorted into three age groups of (n=20) participants: early (ages 2-6), middle (ages 7-11) and late (ages 12-16). Up to 150 control participants will be recruited and split into similar age ranges. Participants will be assessed using step monitoring devices and traditionally performed clinical outcome measures (6MWT, TFTs, NSAA), followed by community monitoring. StepWatch™ data collected from two previously enrolled cohorts of children with DMD will also be used for longitudinal analyses and determination of responsiveness to steroid treatment. We will develop model plans for data collection, validation, visualization, transfer, archival and lock of raw instrument data, as well as guidelines for integration with existing data platforms including EPIC electronic health records and I2B2 NIH data repository.

Applicability: Well-designed community mobility measures can be used in both clinical trials and day-to-day clinical practice. For clinical trials, they provide researchers with the ability to measure day-to-day walking ability across a broad range of ages, including very young children with DMD. Those results can then also be compared to other clinical trial measures such functional evaluations and timed function tests to help teach researchers and regulatory authorities about how “in clinic” tests commonly used in clinical trials relate to a persons’ mobility in their daily life and whether those tests are “clinically meaningful”. Within 3 years, this project will be able to produce such a tool.

Impact and Contributions: Data from this project will provide the basis for development of a “clinical trialready” community mobility measure that has been constructed against a background of comprehensive clinical assessments of functional ability across the range of ambulatory ability. This measure will be rapidly usable as a sensitive measure for use in the growing field of DMD clinical trials, and will help to demonstrate “clinically meaningful” results to regulatory agencies in charge of new drug approval.

2. KEYWORDS: Provide a brief list of keywords (limit to 20 words).

Duchenne muscular dystrophy
Community Mobility
mHealth
Patient Generated Health Data
Accelerometers
Clinical Trial Outcomes Development
DMD Natural History

3. ACCOMPLISHMENTS:

What were the major goals of the project?

Aim 1: Comparison of accuracy and validity of both laboratory- and consumer-grade step activity monitoring devices, and comparison to traditional clinical evaluator determined laboratory-based measures.

- Aim 1.1: Evaluate validity and correlation of stride activity data using laboratory and consumer grade devices.
- Aim 1.2: Determine concurrent validity of stride rate patterns by accelerometry as compared to the 6-minute walk test, North Star Ambulatory Assessment and Timed Motor Performance Tests in DMD patients who are able to perform these assessments.

Aim 2: Evaluation of age-related patterns in community step monitoring data in DMD and typically developing youth controls.

- Aim 2.1 Evaluate differences between DMD and TDY in overall daily patterns of activity by age group
- across all levels of stride rate activity.
- Aim 2.2 Evaluate differences between DMD and TDY for area under the curve for total time and height-adjusted distance overall and at each stride rate and stride activity level group.
- Aim 2.3 Evaluate Differences between age groups that represent disease progression in DMD for area under the curve for total time and height-adjusted distance overall and at each stride rate and stride activity level group.

Aim 3: Evaluation of historical community stride monitoring data from natural history studies and clinical trials to evaluate longitudinal change and steroid response characteristics.

- Aim 3.1 Evaluate longitudinal rate of change characteristics of stride activity monitoring in DMD using
- historical natural history data.
- Aim 3.2 Evaluate longitudinal rate of change characteristics of stride activity monitoring to identify
- differences due to glucocorticoid therapy using historical clinical trial data.

Aim 4: We will develop, evaluate and provide recommendations for a framework to collect, and track patient generated health data in the electronic health record for clinical care and to transfer this data into a database to meet Federal 21CFR11 compliance for clinical research.

- **Aim 4.1:** Develop guidelines for developing a platform to collect PGHD, guidelines for storage,
- visualization and providing clinical care in the EPIC electronic health record.
- **Aim 4.2:** Provide guidelines for the transfer of de-identified patient-generated health data (PGHD) collected via this methodology to meet FDA 21CFR11 compliance. In addition develop guidelines for sharing deidentified PGHD using a platform like the I2B2 NIH data repository for clinical research.

What was accomplished under these goals?

Summary

As we described in our previous progress reports, due to the COVID-19 pandemic, human participant clinic visits were temporarily put on hold in early 2020 on a university-wide basis at UC Davis and throughout the UC system, and this impacted our ability to enroll study participants. Our lab experienced no cessation of *interventional* human studies with prospects for direct benefit to participants, but all other studies were placed on hold pending development of laboratory-specific safety SOPs. Mid-year the university implemented a phased re-start of project elements requiring direct human interaction. This project was designated as a “high-priority” clinical study by the Dean’s Office and was one of the first to be allowed to resume in June 2020 with targeted enrollment of study participants who have been scheduled for regular clinical care visits. This has

enabled us continue to enroll participants in an initial cohort of individuals with Duchenne muscular dystrophy, as well as some typically-developing siblings who were attending visits with their affected brothers. As of Summer 2020 weeks ago, our region/University has relaxed social and research restrictions, and we have ramped up to gather more data from individuals outside of our regular clinic practice.

With the help of our institution's telemedicine and telehealth program leaders, we have explored ways to extend the study into the community using telehealth visits and connected devices to enable us to conduct common clinical evaluations (such as the six-minute walk test and timed motor performance tests) remotely in the home/community environment where we expect we will be able to recruit participants more rapidly. As a part of a separate project funded by the Muscular Dystrophy Association, Dr. Henricson has submitted a protocol that includes novel methods for ZOOM-based data collection in the field. That project was approved by the UC Davis IRB and Office of Research for active enrollment and is now in the process of launching. Dr. Henricson has committed to sharing additional participant data that may be of assistance to interpretation of data being collected under the DoD-sponsored program. As a proof-of-concept, Dr. Henricson and his team recently submitted a paper to *Neuromuscular Disorders* on machine learning-based analysis of temporospatial gait parameters from Apple iPhone devices using combined de-identified lab-based gait sensor data from typically developing and DMD patients from this DoD-sponsored project (Phase II and Phase IV activities) and his CITRIS/Banatao Institute-sponsored project. As part of that effort, the team developed a pilot remote measurement dashboard and clinician dashboard that includes reporting of individual clinical temporal-spatial characteristics of gait, as well as machine learning tools to automatically identify walking and running steps from raw sensor signals, and to discriminate between individuals with typical and atypical gait patterns during different assessments. A copy of that manuscript is attached here.

Phase I Activities: Study Preparation and Initiation

Task 1 – Human Subject Protection Approval Submission to DoD (Months 1-3): The project PI and co-investigators will develop a human subjects protocol and consent documentation for clinical evaluations and will obtain IRB approval from UC. Institutional IRB approvals will be submitted to DoD HRPO for revision and approval. DoD revisions will be reviewed and approved by the Institutional IRB. This task will be completed by Drs. McDonald and Henricson and Mr. Owens. **COMPLETE**

Task 2 – Equipment Procurement and Distribution (Months 1-3): The project coordinator will obtain stride rate monitor systems and other materials required to conduct study evaluations. This task will be completed by Ms. Nicorici and Mr. Branum. **COMPLETE**

Task 3 – Clinical evaluator methodological training for clinical assessments (Month 3): The project investigators and clinical evaluators will meet centrally to harmonize evaluation techniques. This task will be completed by Dr. McDonald, Dr. Henricson, and Ms. Nicorici. **COMPLETE**

Task 4 – RedCap database and electronic data capture system design (Months 2-3): The project data manager will construct a study database and online web-accessible electronic case report form system to ensure accuracy and completeness of data entry. All study evaluation data will be captured using paper-and-pencil clinic worksheets and will be transcribed into electronic forms by study clinical evaluators and study coordinators. Raw data from stride rate monitors will be uploaded and archived as individual files and will be associated with specific participants and visits to facilitate later compilation and analysis. RedCap enables data monitoring and editing features that are compliant with FDA requirements for electronic recordkeeping in clinical trials. The RedCap system is provided free of charge for UC-associated studies via the UC Davis Clinical and Translational Science Center. Additional technical details are available at <http://www.ucdmc.ucdavis.edu/ctsc/redcap/>. This task will be completed by Mr. Owens. **COMPLETE**

Task 5 – Annual IRB Review (Years 2&3, Month 1 *approximately*): Annual human subject protection review activities will be conducted as required by institution IRB and DoD committees. This task will be completed by Drs. McDonald and Henricson and Mr. Sarwari. **COMPLETE**

Task 6- Study Recruiting, Advertising and Outreach via clinic networks, advocacy organizations, patient registries and social media outlets (Year 3, Month 6 – Year 4, Month 6) **IN PROGRESS**

Phase II Activities

Task 1 - Recruit and collect data on 60 DMD and 150 typically-developing children (2-16 years) (Year 3, Month 6 – Year 4, Month 6): Participants will be evaluated per the study evaluation protocol at UC. This task will be completed by Ms. Goude, Ms Nicorici, the project specialist (TBD) and Drs. McDonald and Henricson. **IN PROGRESS**

Task 2 - RedCap electronic data capture (Year 3, Month 6 – Year 4, Month 6): Data from clinical evaluations will be entered into the electronic case report form system. This task will be completed by clinical study team. **IN PROGRESS**

Phase III Activities: Retrospective Data Analysis and Publications

Task 1-2 – Data analysis and development of publications (Year 3-4): Data analysis will be conducted for Aim 3 activities per the study data analysis plan. Investigators will draft manuscripts for publication in a reputable peer-reviewed journal. This task will be completed by Drs. McDonald and Henricson and the study team. **IN PROGRESS**

Phase IV Activities: Development of Data Integration Platform Guidelines

Task 1 - Develop guidelines for electronic data transfer and storage platform construct for community-derived mobile health data for medical records (Year 3-4). As stated in Aim 4.1 activities, investigators will develop guidelines for developing a platform to collect PGHD, guidelines for storage, visualization and providing clinical care in the EPIC electronic health record. This task will be completed by Dr. Dharmar, with input from Drs. McDonald and Henricson. **IN PROGRESS**

Task 2 - Provide guidelines for the transfer of de-identified patient-generated health data (PGHD) to meet FDA 21CFR11 compliance (Year 3-4). As stated in Aim 4.2 activities, investigators will develop guidelines for 21 CFR 11-compliant electronic data transfer and storage platform construct for community-derived mobile health data for research. In addition they will develop guidelines for sharing de-identified PGHD using a platform like the I2B2 NIH data repository for clinical research. This task will be completed by Dr. Dharmar, with input from Drs. McDonald and Henricson. **IN PROGRESS**

Task 3 – Develop a guidance document and manuscript reflecting system design recommendations and implementation (Year 3-4). Investigators will draft a manuscript for publication in a reputable peer-reviewed journal. This task will be completed by Dr. Dharmar, with input from Drs. McDonald and Henricson. **IN PROGRESS**

What opportunities for training and professional development has the project provided?

Nothing to Report

How were the results disseminated to communities of interest?

Results as described above were presented at the following conferences:

1. Ramli A, Henricson EK. An automated system for early diagnosis, severity and progression identification in Duchenne muscular dystrophy: A machine learning and deep learning approach. 7th Annual UC Davis Health Human Genomics Symposium. November 6, 2020. Online.
2. Ramli A, Nicorici A, Prasad P, Hou J, McDonald CM, Liu X, Henricson EK. Gait Characterization in Duchenne Muscular Dystrophy (DMD) Using a Single-Sensor Accelerometer: Classical Machine Learning and Deep Learning Approaches. June 23-26, 2021 Parent Project Muscular Dystrophy Annual Conference. Online.
3. Liu X, Henricson E. Human activity recognition through wearable sensors. UC Davis Health Data Science Brown Bag Talks. UC Davis DataLab/Data Science and Informatics Program. June 11, 2021. Online.

Results as described above were submitted as the following manuscript:

1. Ramli A, Zhang H, Hou J, Liu R, Nicorici A, Aranki D, Owens C, Prasad P, McDonald CM, Henricson EK. Gait Characterization in Duchenne Muscular Dystrophy (DMD) Using a Single-Sensor Accelerometer: Classical Machine Learning and Deep Learning Approaches. Neuromuscular Disorders (Submitted)

What do you plan to do during the next reporting period to accomplish the goals?

Within constraints due to COVID-19-related clinical research safety practices (see Actual or Anticipated Problems section below), we are presently enrolling and testing study participants per the approved study protocol and the revised Statement of Work.

4. IMPACT:

What was the impact on the development of the principal discipline(s) of the project?

Nothing to Report

What was the impact on other disciplines?

Nothing to Report

What was the impact on technology transfer?

Nothing to Report

What was the impact on society beyond science and technology?

Nothing to Report

5. CHANGES/PROBLEMS:

Changes in approach and reasons for change

Please refer to our progress statement for information regarding the team's response to COVID-19 pandemic-related delays in this project. Given these events and challenges, our present plan is to continue in a no-cost extension year per our last approved revision of our project Statement of Work. We will continue to adjust our implementation of the study to comply with any University COVID-19 restrictions and are developing telehealth-based assessment methods. If the new methodology proves feasible, we will update our study protocol to allow for remote visit conduct.

Actual or anticipated problems or delays and actions or plans to resolve them

Please refer to our progress statement for information regarding the team's response to COVID-19 pandemic-related delays in this project. Given these events and challenges, our present plan is to continue in a no-cost extension year per our last approved revision of our project Statement of Work. We will continue to adjust our implementation of the study to comply with any University COVID-19 restrictions and are developing telehealth-based assessment methods.

Changes that had a significant impact on expenditures

Nothing to Report.

Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents

Nothing to Report

Significant changes in use or care of human subjects

Nothing to Report

Significant changes in use or care of vertebrate animals

Nothing to Report

Significant changes in use of biohazards and/or select agents

Nothing to Report

6. PRODUCTS:

Publications, conference papers, and presentations

As noted above in the dissemination section.

Journal publications

As noted above in the dissemination section.

Books or other non-periodical, one-time publications.

Nothing to Report

Other publications, conference papers and presentations.

Nothing to Report

Website(s) or other Internet site(s)

Nothing to report

• **Technologies or techniques**

Nothing to Report

• **Inventions, patent applications, and/or licenses**

Nothing to Report

• **Other Products**

Nothing to Report

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

What individuals have worked on the project?

Name: Craig McDonald, MD (PI) - No Change
Name: Erik Henricson, MPH (Co-Investigator) - No Change
Name: Madan Dharmar, PhD (Co-Investigator) - No Change
Name: Alina Nicorici, BS (Clinical Evaluator) - No Change

Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

Yes. Please refer to updated Other Support documents.

What other organizations were involved as partners?

Nothing to Report

8. SPECIAL REPORTING REQUIREMENTS

COLLABORATIVE AWARDS:

QUAD CHARTS:

9. APPENDICES:

1. Please see the attached revised study timeline from our previously-submitted request for a no-cost extension (August 2, 2021)
2. Please see the attached manuscript, submitted to Neuromuscular Disorders.

APPENDIX 1: Revised Study Timeline (August 2, 2021)

Objectives and Specific Aims

This proposal focuses on validating the use of patient generated step and activity data to facilitate future data collection at the point-of-care to support the development of stride rate patterns as an outcome measure for ambulatory patients with DMD. It is to include step activity monitoring by StepWatch™ and a consumer level step monitoring devices (Garmin VivoActiveHR and Polar M400 activity watches and the Polar StrideSensor activity monitor) that can feed data through Apple HealthKit into the UC Davis instance of the Epic electronic medical record system. Up to 60 ambulatory patients with DMD will be recruited to represent the early, middle and late stages of the progressive loss of ambulation in DMD. Patients will be sorted into three age groups of (n=20) participants: early (ages 2-6), middle (ages 7-11) and late (ages 12-16). Up to 150 control patients will be recruited and split into similar age ranges. Participants will be assessed using step monitoring devices and traditionally performed clinical outcome measures (6MWT, TFTs, NSAA), followed by community monitoring. StepWatch™ data collected from two previously enrolled cohorts of children with DMD will also be used for longitudinal analyses and determination of responsiveness to steroid treatment. We will address the following specific aims:

Aim 1: Comparison of accuracy and validity of both laboratory- and consumer-grade step activity monitoring devices, and comparison to traditional clinical evaluator determined laboratory-based measures.

Aim 1.1: Evaluate validity and correlation of stride activity data using laboratory and consumer grade devices.

Aim 1.2: Determine concurrent validity of stride rate patterns by accelerometry as compared to the 6-minute walk test, North Star Ambulatory Assessment and Timed Motor Performance Tests in DMD patients who are able to perform these assessments.

Aim 2: Evaluation of age-related patterns in community step monitoring data in DMD and typically developing youth controls.

Aim 2.1 Evaluate differences between DMD and TDY in overall daily patterns of activity by age group across all levels of stride rate activity.

Aim 2.2 Evaluate differences between DMD and TDY for area under the curve for total time and height-adjusted distance overall and at each stride rate and stride activity level group.

Aim 2.3 Evaluate Differences between age groups that represent disease progression in DMD for area under the curve for total time and height-adjusted distance overall and at each stride rate and stride activity level group.

Aim 3: Evaluation of historical community stride monitoring data from natural history studies and clinical trials to evaluate longitudinal change and steroid response characteristics.

Aim 3.1 Evaluate longitudinal rate of change characteristics of stride activity monitoring in DMD using historical natural history data.

Aim 3.2 Evaluate longitudinal rate of change characteristics of stride activity monitoring to identify differences due to glucocorticoid therapy using historical clinical trial data.

Aim 4: We will develop, evaluate and provide recommendations for a framework to collect, and track patient generated health data in the electronic health record for clinical care and to transfer this data into a database to meet Federal 21CFR11 compliance for clinical research.

Aim 4.1: Develop guidelines for developing a platform to collect PGHD, guidelines for storage, visualization and providing clinical care in the EPIC electronic health record.

Aim 4.2: Provide guidelines for the transfer of de-identified patient-generated health data (PGHD) collected via this methodology to meet FDA 21CFR11 compliance. In addition develop guidelines for sharing de-identified PGHD using a platform like the I2B2 NIH data repository for clinical research.

Project Timeline (REVISED)

Study-specific tasks and activities are displayed in the table below.

Project/Task	Year 1				Year 2-3				Year 4				Year 5			
	1	2	3	4	1-2	3-4	1-2	3-4	1	2	3	4	1	2	3	4
Phase I: Study Preparatory and Initiation Activities																
Develop Study Protocol and obtain IRB approvals (Institutional and DoD)	C															
Equipment Procurement and Distribution	C															
Site evaluator methodological training for functional assessments	C															
Database and electronic data capture system setup	C															
Annual IRB Review					C				X				X			
Study Recruiting, Advertising and Outreach via clinic networks, advocacy organizations, patient registries and social media outlets.		X	X	X	X	X	X	X	X	X	X	X	X	X	X	
Phase II: Clinical Study Conduct (Aims 1 and 2)																
Recruit and collect data on 60 DMD children and 150 controls (age 2-16 years).					X	X	X	X	X	X	X	X	X	X	X	
Electronic data capture, data monitoring and cleaning.					X	X	X	X	X	X	X	X	X	X	X	
Database lock									X						X	
Analyze data. Write up paper regarding Aim 1.1 on reliability and validity data.									X	X	X			X	X	
Analyze data. Write up paper regarding Aim 1.2 on comparisons with community and clinical measures.									X	X	X			X	X	
Analyze data. Write up paper regarding Aim 2.1 and 2.2 on comparison of activity patterns in DMD vs controls.										X	X	X		X	X	X
Analyze data. Write up paper regarding Aim 2.3 on comparison of activity patterns with DMD progression										X	X	X		X	X	X
Phase III: Retrospective Data Analysis and Publications (Aim 3)																
Analyze data. Write up paper regarding Aim 2.1 on 1-year longitudinal change using McDonald Shriners' Hospital consortium data.		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Analyze data. Write up paper regarding Aim 2.2 on magnitude of glucocorticoid effect using PTC Therapeutics clinical trial group data.					X	X	X	X	X	X	X	X	X	X	X	X
Phase IV: Development of data integration platform guidelines (Aim 4)																
Develop guidelines for electronic data transfer and storage platform construct for community-derived mobile health data for medical records.	X	X	X	X					X	X	X	X	X	X	X	X
Develop guidelines for 21 CFR 11-compliant electronic data transfer and storage platform construct for community-derived mobile health data for research.				X	X	X	X		X	X	X	X	X	X	X	X
Simulate and test community step data transfer process from consumer device through EPIC EMR and research databases.							X	X	X	X	X	X	X	X	X	X
Write up paper regarding Aim 4 platform guidelines and recommendations.									X	X	X	X	X	X	X	X